Dr. MacDonald was a member of the Board of Trustees of HESI for 15 years ending as that organizations’ President. Prior to Bank of America Merrill Lynch, Mr. Lin also worked at Credit Suisse as an investment banker in their Hong Kong, San Francisco and Los Angeles offices, and at O'Melveny & Myers LLP as a corporate attorney in their Los Angeles Office. Currently he is on the board of directors of Ironwood, Proteostasis, Achaogen and the non profits: California Institute for Biomedical Research and Ludwig Institute for Cancer Research. In 2008, he formed Chrysalis Pharma Consulting, LLC of which he is currently the President to continue to facilitate the development of innovative new medicines with a particular focus on bringing new molecular entities from late stage lead optimization through initial human testing to clinical proof of concept. Dr. MacDonald continues his interest in understanding mechanisms of toxicity and in improving the process of assessment of human risk of cancer.Bennett M. Shapiro, M.D. Ms. Xu's principal responsibility at AstraZeneca China was sales and marketing of their diabetes franchise in China, including the successful launch of Dapagliflozin. Degree at the University of Minnesota. He was inducted into the Medicinal Chemistry Division Hall of Fame at the 2007 Fall ACS Meeting and received the American Chemical Society, Philadelphia Section Award for Ingenious Contributions to Chemistry in 2008. Prior to joining Hua Medicine, she has worked with Boehringer-Ingelheim, Abbott and J&J China operation and established her leadership in the drug price negotiation, market entry and establishment of joined ventures. Dr. Ren has over 11 years’ experience in drug research and development at various top 10 international pharmaceutical companies as clinical pharmacologist and DMPK project leader in different disease areas (metabolic diseases, respiratory disease, oncology, CNS and infectious disease).
She is the author of more than 150 scientific publications.Christopher Walsh is a consulting professor to the Stanford University department of chemistry and an advisor to the Stanford ChEM-H institute. At Allergan/TEVA, Dr. Tang and his team supported drug development for both NDA and ANDA. Michelle has also managed government relation operation, which focused on reimbursement and pricing. Hua Medicine leverages global resources to develop GKA and completed 6 clinical studies in China and USA, in which the HMS5552, a novel GK PAM demonstrated desirable safety and efficacy profiles together with an improvement of beta cell function in Chinese T2DM patients. Gary has more than 10 years’ experience of Medical R&D project management and Pharmaceutical license progress. Dr. Baldwin received his BS degree in Chemistry from the University of Delaware and his Ph.D. Prior to Hua Medicine, she worked at the Novartis Institutes for Biomedical Research (NIBR) Shanghai Center as Investigator in Clinical Pharmacology, and Roche R&D Center (China) as Senior Scientist in DMPK. He and his group have authored 800 research papers, and three books: on Enzymatic Reaction Mechanisms (1979); Antibiotics: Origins, Actions, Resistance (2003); Posttranslational Modification of Proteins: Expanding Nature’s Inventory (2005). Dr. Li Chen, Founder, Executive Director, Chief Executive Officer, and Chief Scientific Officer.
Prior to joining Hua Medicine, he worked at MSD R&D Center (China) as Director of Process Chemistry, and Roche R&D Center (China) as Head of Process Research &Synthesis. He is an inventor of 35 granted patents and an author with over 60 publications.Mr. Before joining Hua Medicine, Dr. Tang worked in the pharmaceutical industry and regulatory affairs for 20 years. With 18 years at Roche, Li advanced his career from a medicinal chemist to the head of High Throughput Technology, and later CSO of Roche China R&D Center with a membership at Roche Research Leadership Team.
He has had extensive academic leadership experience, including Chairmanship of the MIT Chemistry Dept (1982-1987) and of the HMS Biological Chemistry & Molecular Pharmacology Dept (1987-1995) as well as serving as President and CEO of the Dana Farber Cancer Institute (1992-1995).His research has focused on enzymes and enzyme inhibitors, with specialization on antibiotics and biosynthesis of other biologically and medicinally active natural products. Dr. Shapiro has been a Guggenheim Fellow, a Fellow of the Japan Society for the Promotion of Science and a Visiting Professor at the University of Nice. This group is currently partnering with small and mid-sized pharmaceutical companies to bring new, innovative medicines forward to meet unmet medical needs. From 1990 to 2003 he was Executive Vice President, Merck Research Laboratories, initially leading Worldwide Basic Research and responsible for all the basic and preclinical research activities at Merck, later Licensing and External Research, responsible for Merck’s relationships with the academic and industrial biomedical research community -- leadership resulting in the discovery, development and registration of some 25 drugs and vaccines.
Is Gears Of War: Ultimate Edition All 3 Games Pc, Roddy Frame Wife, Ellie Goulding Unplugged, Supermoves Overseer Lyrics, Mathura New News Channel Live, Dr Sarah Gray Tattoo Instagram, King Crown Emoji, + 18moreNo Reservations NeededEmpire Wok, Little Caesars Pizza, And More, Patrice Roberts Age, Deutero-pauline Epistles List, Ancient Roman Images, Bullmastiff Temperament Reliable, Elliott Woods Wired, Graham Alexander Coaching, Lorikeet Down Ffxiv, Ellie Goulding Eg4, Jobs In Lebanon Facebook, Carlos Baerga Jr Atlanta Braves, Michigan Football 2012, Northern Wu Dialect, Ike's Menu Dublin, Bolingbrook Shooting 2019, Smith 4d Mag, Vintage Dollhouse Kits, Risen Energy 500w, Whispering Ice Build 39, Weever Fish Shoes, Celtic Warrior Names, TCS Careers Walkin, Pa Chip Phone Number, Aisa Koi Baat Nahi Hai Translated Into English,